![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Issues Revised ICH Risk-Benefit Submission Guidance
FDA Issues Revised ICH Risk-Benefit Submission Guidance
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
July 27, 2017
The FDA issued a revised version of its ICH-developed guidance on completing the clinical overview section of the Common Technical Document, including more details on risk-benefit submissions.
The guidance, known as M4E(R2), lists what sponsors should consider when describing risks and benefits, but does not specify a particular industry approach for completing assessments.
An ICH working group said the section of the CTD weighing benefits and risks — section 2.5.6, which also includes information on therapeutic context — should succinctly describe the sponsor’s thought process, but not present new data.
Upcoming Events
-
21Oct